Giorgia Mangili, Giorgio Giorda, Gabriella Ferrandina, Gennaro Cormio, Chiara Cassani, Antonella Savarese, Saverio Danese, Marco Carnelli, Francesca Maria Vasta, Anna Myriam Perrone, Giovanna Scarfone, Sandro Pignata, Francesco Legge, Francesco Raspagliesi, Gianluca Taccagni, Massimo Candiani, Giorgio Bogani, Floriana Mascilini, Alice Bergamini
OBJECTIVE: The aim of this study was to analyze the oncological outcome of stage I malignant ovarian germ cell tumors patients included in the MITO-9 study to identify those who might be recommended routine surveillance alone after complete surgical staging. METHODS: MITO-9 was a prospective observational study analyzing data collected between January 2013 and December 2019. Three groups were identified: group A included 13 patients stage IA dysgerminoma and IAG1 immature teratoma; group B included 29 patients with stage IB-C dysgerminomas, IA-C G2-G3 immature teratomas and stage IA mixed malignant ovarian germ cell tumors and yolk sac tumors; and group C included five patients (two patients with stage IC1 and one patient with stage IC2 yolk sac tumors and two patients with mixed-stage IC2 malignant ovarian germ cell tumors)...
September 2021: International Journal of Gynecological Cancer